Clindacyl Tablets are indicated for the treatment of infected wounds, abscesses, superficial pyoderma and oral cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, bacteroidaceae, Fusobacterium necrophorum, Clostridium perfringens and osteomyelitis caused by Staphylococcus aureus in dogs. Clindacyl Tablets can also be used to help provide antimicrobial cover during dental procedures. Clindacy Tablets are available in 4 sizes: Clindacyl Tablets 25mg, Clindacyl Tablets 75mg, Clindacyl Tablets 150mg and Clindacyl Tablets 300mg.

Contra-indications/Warnings
Do not administer to animals with hypersensitivity to clindamycin and lincomycin preparations.
Do not administer to rabbits, guinea pigs, chinchillas, hamsters, horses or ruminants.

Special warnings
Before use of Clindacyl tablets, the identification of causative pathogenic micro-organisms should be carried out and their susceptibility to clindamycin should be established.
Clindamycin and lincomycin show parallel resistance. There is a partial cross-resistance to erythromycin and other macrolide antibiotics.

Special precautions for use in animals
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high dose clindamycin therapy.

Adverse reactions (frequency and seriousness)
Clindamycin sometimes causes the overgrowth of non sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures should be taken according to the clinical situation.
Vomiting and diarrhoea are observed occasionally.

Use during pregnancy and lactation
While high dose studies in rats suggests that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches or breeding male dogs has not been established.

Interaction with other medicinal products and other forms of interaction
Neuromuscular blocking effects have been observed with clindamycin possibly leading to an increase of efficacy of other neuromuscular blocking agents. The concomitant use of such drugs must be handled with care.
Clindamycin should not be used concomitantly with chloramphenicol or macrolides because they may antagonise each other at the site of action.

Operator warning
None

Overdose
Symptoms of overdose include vomiting, inappetency and diarrhoea. In such cases, treatment should be stopped immediately and the dogs treated symptomatically.

Withdrawal periods
Not applicable

Further information
Clindamycin, a chlorinated analogue of lincomycin, is an antibiotic with bacteriostatic action. Bactericidal actions have also been reported.
Clindamycin is rapidly absorbed; following oral administration up to 90% of the active ingredient is absorbed from the gastro-intestinal tract.
Bioavailability is greater in fasting dogs than fed dogs.
Clindamycin crosses the placental barrier and can be detected in milk.